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Abstract
To investigate whether therapeutic hypothermia augments the restorative impact of protein kinase C-β (PKC-β) and Nox2 
inhibition on an in vitro model of human blood–brain barrier (BBB). Cells cultured in normoglycaemic (5.5 mM) or hyper-
glycaemic (25 mM, 6 to 120 h) conditions were treated with therapeutic hypothermia (35 °C) in the absence or presence of 
a PKC-β inhibitor (LY333531, 0.05 μM) or a Nox2 inhibitor (gp91ds-tat, 50 μM). BBB was established by co-culture of 
human brain microvascular endothelial cells (HBMECs) with astrocytes (HAs) and pericytes. BBB integrity and function 
were assessed via transendothelial electrical resistance (TEER) and paracellular flux of sodium fluorescein (NaF, 376 Da). 
Nox activity (lucigenin assay), superoxide anion production (cytochrome-C reduction assay), cellular proliferative capacity 
(wound scratch assay) and actin cytoskeletal formation (rhodamine-phalloidin staining) were assessed both in HBMECs 
and HAs using the specific methodologies indicated in brackets. Therapeutic hypothermia augmented the protective effects 
of PKC-β or Nox2 inhibition on BBB integrity and function in experimental setting of hyperglycaemia, as evidenced by 
increases in TEER and concomitant decreases in paracellular flux of NaF. The combinatory approaches were more effective 
in repairing physical damage exerted on HBMEC and HA monolayers by wound scratch and in decreasing Nox activity and 
superoxide anion production compared to sole treatment regimen with either agent. Similarly, the combinatory approaches 
were more effective in suppressing actin stress fibre formation and maintaining normal cytoskeletal structure. Therapeutic 
hypothermia augments the cerebral barrier-restorative capacity of agents specifically targeting PKC-β or Nox2 pathways.
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Introduction
Ischaemic stroke stemming from an interference with blood 
supply leading to or within the brain continues to be one 
of the main causes of mortality and morbidity worldwide. 
Disruption of the blood–brain barrier (BBB) and ensuing 
vasogenic oedema constitute the main causes of neurologi-
cal impairment during the acute phase of ischaemic strokes 
(Alwjwaj et al. 2021; Jiang et al. 2018). Prolonged exposure 
to hyperglycaemia in patients with diabetes mellitus (DM) 
amplifies the extent of stroke-mediated BBB disruption 
through thickening of the capillary basement membrane and 
increases in oxidative stress, neuronal and endothelial cell 
apoptosis (Venkat et al. 2017). Unsurprisingly, ischaemic 
stroke patients with DM suffer worse outcomes than those 
without (Thorén et al. 2017; Yu et al. 2016). Hyperglycaemia 
also negates the beneficial effect of the recombinant tissue 
plasminogen activator (rtPA), the only approved pharmaco-
therapeutic agent, and is coupled to higher rates of intracra-
nial haemorrhage (Masrur et al. 2015). Since less than 5% of 
patients with ischaemic stroke receive rtPA due to a narrow 
therapeutic window (first 4.5 h of stroke onset), search for 
an alternative therapeutic regimen continues (Kadir et al. 
2020; Kadir and Bayraktutan 2019). Although mechani-
cal thrombectomy somewhat addresses the issue pertain-
ing to limited therapeutic time window, it is only effective 
in ischaemic stroke stemming from large vessel occlusion 
and requires advanced facilities and technical resources for 
application (Turc et al. 2019). Hence, exploration of novel 
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therapeutic agents and approaches to treat patients continues 
to be a pressing need in stroke medicine.
Therapeutic hypothermia, defined by a core body tem-
perature ≤ 35 °C, is routinely used to minimise deleterious 
effects in global hypoxia-mediated cerebral injury in coma-
tose patients suffering cardiac arrest and in neonates with 
hypoxic-ischaemic encephalopathy (Bernard et al. 2002; 
Shankaran et al. 2005). The application of therapeutic hypo-
thermia with rtPA or mechanical thrombectomy appears to 
be safe and feasible for patients with ischaemic stroke and 
is associated with reduced infarct size and neurological defi-
cits in animal model of ischaemic stroke (Chen et al. 2016; 
Piironen et al. 2014; van der Worp et al. 2007). However, 
the effect of therapeutic hypothermia in experimental and 
clinical settings associated with hyperglycaemia remains 
unknown.
Oxidative stress, characterised by excessive availability 
of reactive oxygen species (ROS), in particular superoxide 
anion, has been shown to account for much of the hyper-
glycaemia-mediated appearance of endothelial dysfunction 
and ensuing vascular complications. Indeed, endothelial 
dysfunction represents a key early and potentially revers-
ible event in diabetic ischaemic stroke to which activation 
of NADPH oxidase (Nox) and PKC-β appear to contribute 
the most (Bayraktutan 2002; Shao and Bayraktutan 2013),. 
Amongst all Nox isoforms, Nox2 is more closely associated 
with the cerebral injury (Kahles and Brandes 2012). Hence, 
it is no surprise that the inhibition of either PKC-β or Nox2 
activity shows a protective effect on BBB, most likely due 
to inactivation of Rho kinase, attenuation of oxidative stress 
and reorganisation of actin cytoskeleton formation (Kahles 
et al. 2007; Shao and Bayraktutan 2013).
In light of the available data, the current study investi-
gates whether strategies combining therapeutic hypother-
mia with agents targeting either PKC-β or Nox2 may bet-
ter protect the integrity and function of an in vitro model 
of human BBB against hyperglycaemic insult. Further-
more, the present study also investigates how these com-
binatory approaches compare against the single treatment 
regimens for wound repair, oxidative stress regulation and 
actin cytoskeletal formation using the two main compo-




HBMECs, human astrocytes (HAs) and human pericytes 
(HPs) were purchased from TCS CellWorks Ltd. (Bucking-
ham, UK) and cultured in respective specialised media (Sci-
encell, Caltag Systems, Buckingham, UK) in a humidified 
atmosphere under normal conditions (75%  N2, 20%  O2 and 
5%  CO2). In related studies, cells were cultured to about 60% 
confluence and were subjected to normoglycemia (5.5 mM 
D-glucose) or hyperglycaemia (25 mM D-glucose) in the 
presence or absence of hypothermia (35ºC), PKC-β inhibitor 
(LY333531, 0.05 μM, Sigma) or Nox2 inhibitor (gp91ds-tat, 
50 μM, SynPeptide, Shanghai, China). The concentration of 
the inhibitors used in the current study were selected according 
to the previous studies (Rey et al. 2001; Shao and Bayraktutan 
2013, 2014; Zinkevich et al. 2017). To investigate the effect 
of combinatory approaches, LY333531 or gp91ds-tat were 
added to culture media and exposed to therapeutic hypother-
mia. The culture media was changed every other day during 
extended exposure to hyperglycaemia (6–120 h). Cell culture 
under normoglycemic and normothermic conditions served as 
controls. Considering that various therapeutic agents such as 
Rho kinase inhibitor (Gibson et al. 2014), anti-oxidant com-
pounds (catalase, vitamin C and E) (Allen and Bayraktutan 
2009), NADPH oxidase inhibitor (Abdullah and Bayraktutan 
2014), anti-TNF-α (Abdullah et al. 2015), and calcium inhibi-
tor (Rakkar and Bayraktutan 2016) protected BBB integrity 
and function against ischaemic/reperfusion, hyperglycaemic, 
or TNF-α injury in our previous studies and those studies uti-
lised similar experimental settings, such positive control was 
not utilised in the present study. Moreover, given that exposure 
to therapeutic hypothermia in clinical settings equally affects 
both damaged and normal cells, we have investigated whether 
and how hypothermia modulates the parameters studied in the 
current study in cells maintained under normoglycaemic con-
ditions (Bobi et al. 2020). However, PKC-β or Nox2 pathways 
are targeted only in pathological conditions such as hypergly-
caemic injury, their effects in physiological settings have not 
been probed. Furthermore, as increases in osmolality, attained 
by the addition of D-mannitol, did not affect BBB integrity 
and function as well as PKC-β and Nox signalling pathways 
in any way compared to normoglycaemic controls, the effect 
of osmolality has not been reassessed in this study (Shao and 
Bayraktutan 2014; Srivastava et al. 2013).
Establishment of an in vitro model of human blood–
brain barrier
Since astrocyte end feet cover the entire endothelial layer and 
the direct contact between astrocytes and endothelial cells 
in the presence of pericytes produce the highest electrical 
resistance compared to non-contact or monolayer models, 
the triple culture model consisting of HBMECs, HAs and 
HPs was used in the present study (Allen and Bayraktutan 
2009; Shao and Bayraktutan 2013). In brief, approximately 
7.5 ×  104 HAs were seeded on the basolateral side of poly-
ester Transwell inserts (0.4 µm pore size, 12 mm diameter 
polyester membrane, High Wycombe, UK). Following over-
night adherence, the inserts were inverted the correct way 
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and placed into 12-well dishes containing fresh medium to 
grow to about 80% confluence. HBMEC (~ 5 ×  104 cells) 
were then added to the inner part of the insert and both cell 
layers were left to grow to full confluence. To set up the tri-
ple-culture model, these Transwell inserts were transferred 
to 12-well plate containing confluent pericytes.
Assessment of BBB characteristics
The integrity and function of the BBB were assessed as before 
by measurements of transendothelial electrical resistance 
(TEER, World Precision Instruments, Hertfordshire, UK) 
and paracellular flux of low molecular weight permeabil-
ity marker, sodium fluorescein (NaF, 376 Da), respectively 
(Rakkar and Bayraktutan 2016). After exposure to their 
respective treatments, TEER across cellular barrier was meas-
ured using STX electrodes and an EVOM resistance meter. 
Two independent readings were taken and the measurements 
of blank filter were subtracted from inserts seeded with cells. 
Values are shown as Ωcm2 based on surface area of insert 
membrane. To measure NaF flux, inserts were washed twice 
with Hank’s Balanced Salt Solution (HBSS) and subsequently 
transferred to fresh 12-well plates containing 2 mL of HBSS. 
NaF (500 μL, 10 μg/mL) was carefully added to the luminal 
chamber and samples were taken in triplicate from both the 
luminal and abluminal chambers after incubation for 60 min 
at 37 °C. The average concentration of dye in each chamber 
was determined by measuring the fluorescence (excitation 
485 nm and emission 520 nm) of samples with FLOUstar 
Omega Plate Reader (BMG Labtech Ltd., UK). Flux was 
expressed by NaF clear volume from the luminal chamber 
and calculated by using the following formula [(reading from 
abluminal chamber × 500) / reading from luminal chamber].
Wound scratch assay
HBMEC and astrocytes were seeded in 6-well plates 
(1.5 ×  105 cells/well) and grown to full confluence before 
scratching the monolayers with a p1000 micropipette tip to 
induce a wound. The cells were then washed with PBS to 
remove the debris. Considering higher proliferative rates 
of HBMECs compared to HAs, pictures of wound closure 
were taken 24 and 48 h after scratch for HBMECs and HAs, 
respectively. The wound closure rates were quantified as 
the percentage of difference in scratch area at the beginning 
(immediately after scratch) and at the indicated time points 
using ImageJ software (version 1.52 k, NIH, Maryland, 
USA). Given the difficulties associated with the visualisa-
tion of particular cell layers in the triple culture system, the 
proliferative capacity both HBMECs and HAs in the present 
study was assessed using HBMEC and HA monolayers sub-
jected to wound scratch (Abdulkadir et al. 2020).
Measurement of Nox activity and superoxide anion 
generation
Nox activity was measured with the lucigenin chemilumi-
nescence assay as previously described (Rakkar and Bayrak-
tutan 2016). The HBMECs or HAs homogenates (~ 50 μg) 
were incubated at 37 °C in assay buffer containing potassium 
phosphate buffer (300 mM, pH 7.0, Sigma), ethylene glycol 
tetraacetic acid (50 mM, Sigma), sucrose (1 M, Sigma) and 
lucigenin (200 μM, Sigma). To eliminate the contributions of 
other ROS-generating enzymes to overall superoxide anion 
generation, the specific inhibitors for nitric oxide synthase 
(NG-nitro-L-arginine methyl ester, 10 mM, Sigma), mito-
chondrial respiratory chain complex 1 (rotenone, 10 mM, 
Sigma), xanthine oxidase (allopurinol, 10 mM, Sigma) and 
cyclooxygenase (indomethacin, 10 mM, Sigma) were also 
added to assay buffer. NADPH (100 μmol/L, Calbiochem, 
UK) was added to initiate the reaction after 15 min. The 
reaction was monitored every minute for 2 h and the rate 
of reaction was calculated using a luminometer (FLUOstar 
Omega, BMG Labtech, Aylesbury, UK).
The levels of superoxide anion were detected by 
cytochrome-C reduction assay (Rakkar and Bayraktutan 
2016). In brief, equal amounts of homogenate (100 μg) 
were incubated with assay buffer containing HEPES (1 M, 
Calbiochem, UK), ethylene glycol tetraacetic acid (50 mM, 
Sigma), sucrose (1 M, Sigma), mannitol (1 M, Sigma) and 
cytochrome C (800 μM, Sigma), for 1 h at 37 °C. Super-
oxide anion generation was measured as the reduction of 
cytochrome C and monitored with the change in absorbance 
at 550 nm using a plate reader (FLUOstar Omega, BMG 
Labtech, Aylesbury, UK).
Immunocytochemistry
HBMECs and HAs were grown to about 80% confluence 
on coverslip. The cells were fixed and permeabilised with 
4% paraformaldehyde/PBS for 20 min and with 0.1% Triton 
X-100/PBS for 15 min, respectively. The cells then were 
stained with 1 × rhodamine phalloidin for 30 min (Abcam, 
Cambridge, UK) in the dark room and the coverslips sub-
sequently were mounted on glass slides. Each experiment 
was performed in triplicate and the representative images 
obtained from five random fields on each coverslip were 
analysed by two different investigators using fluorescence 
microscopy (Zeiss Axio Observer, Carl Zeiss Ltd, Cam-
bridge, UK). The length of stress fibres formed was meas-
ured using ImageJ software (version 1.52 k, NIH, Maryland, 
USA). Due to the difficulties pertaining to effective visuali-
sation of stress fibre formation in different cell layers of a 
triple culture model, F-actin staining were performed using 
the HBMEC and HA monolayers (Abdulkadir et al. 2020).
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Statistical analysis
Data are presented as the mean ± SEM from at least 
three independent experiments. Statistical analyses 
were performed using GraphPad Prism 8.0 statisti-
cal software package (GraphPad Software Inc). Data 
were analysed by one-way ANOVA followed by a 
Tukey post hoc analysis. P < 0.05 was considered as 
significant.
Results
Therapeutic hypothermia augments 
the barrier‑restorative effects of PKC‑β or Nox2 
inhibition
Exposure of the triple culture model of human BBB to 
hyperglycaemia significantly impaired BBB integrity and 
function, as observed by significant decreases in TEER and 
concurrent increases in paracellular flux of NaF across the 
Fig. 1  Schematic diagram summarising the establishment of an 
in  vitro model of human BBB (A). The Transwell insert were 
inverted and human astrocytes (HAs) were seeded on the basal side 
of the insert. Once the cells were attached, the inserts were returned 
to their original orientation. Human brain microvascular endothelial 
cells (HBMEC) were seeded on the apical side of the insert once 
the HAs reached 90% confluence. The inserts were then transferred 
to a 12-well plate containing confluent human pericytes. The meas-
urement of BBB integrity and function by TEER B and NaF flux C, 
respectively. BBB were exposed to 120 h hyperglycaemia and treated 
with therapeutic hypothermia alone or together with LY333531 and 
gp91ds-tat. While exposure to hyperglycaemia significantly compro-
mised BBB integrity and function, treatment with single therapies 
i.e. therapeutic hypothermia, PKC-β, or Nox2 inhibitor attenuated 
the impact of HG on BBB integrity and function. The combinatory 
approaches showed better protection on BBB compared to any sin-
gle treatment. Interestingly, exposure to therapeutic hypothermia 
in normoglycaemic settings disrupted BBB integrity and function, 
albeit the degree of impairment was substantially lesser than those 
induced by hyperglycaemia Data are expressed as mean ± s.e.m. from 
three different experiments. *P < 0.05 versus normoglycaemia (NG), 
#P < 0.05 versus HG, ΨP < 0.05 versus HG + TH, γP < 0.05 versus 
HG + LY333531, and ςP < 0.05 versus gp91ds-tat. NG, normoglycae-
mia; HG, hyperglycaemia; TH, therapeutic hypothermia
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barrier, respectively. Interestingly, exposure to therapeutic 
hypothermia (35 °C) alone also compromised the integ-
rity and function of the BBB in normoglycaemic settings, 
albeit the magnitudes of impairment were significantly 
lesser than those induced by hyperglycaemia. While the 
inhibition of PKC-β or Nox2 improved BBB integrity and 
function in a similar manner to therapeutic hypothermia 
in hyperglycaemic settings, the combination of therapeu-
tic hypothermia with either inhibitor almost completely 
neutralised the deleterious effect of hyperglycaemia on 
barrier integrity or function, proving a synergism in effect 
(Fig. 1).
Therapeutic hypothermia accelerates the speed 
of wound repair induced by inhibition of PKC‑β 
or Nox2
To ascertain how combining therapeutic hypothermia with 
an inhibitor for PKC-β signalling pathway or Nox2 enzyme 
Fig. 2  The effects of single 
or combinatory treatments 
with therapeutic hypothermia, 
LY333531 and gp91ds-tat on 
human brain microvascular 
endothelial cells (HBMEC) 
wound closure. While exposure 
to hyperglycaemia dramati-
cally supressed the speed of 
HBMEC wound closure, the 
combination of therapeutic 
hypothermia with LY333531 or 
gp91ds-tat substantially acceler-
ated HBMEC wound closure 
compared to all single treat-
ment options (A). Moreover, 
the exposure of HBMECs to 
therapeutic hypothermia under 
normal conditions did not alter 
the wound reparative capacity 
of this particular cells. Graph 
showing the wound closure 
speed across all experimental 
groups (B). Data are expressed 
as mean ± s.e.m. from three 
different experiments. *P < 0.05 
versus normoglycaemia (NG), 
#P < 0.05 versus HG, ΨP < 0.05 
versus HG + TH, γP < 0.05 
versus HG + LY333531, and 
ςP < 0.05 versus gp91ds-tat. 
NG, normoglycaemia; HG, 
hyperglycaemia; TH, therapeu-
tic hypothermia
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affects the proliferation and migration of main cellular compo-
nents of the BBB, a wound was generated on HBMEC and HA 
monolayers by scratch. The application of therapeutic hypo-
thermia, PKC-β (LY333531) or Nox2 (gp91ds-tat) inhibitor 
alone repaired the physical damage introduced on HBMEC 
and HA monolayers in hyperglycaemic settings. Combination 
of therapeutic hypothermia with LY333531 or gp91ds-tat 
accelerated the reparative effect of both inhibitors compared 
to all single treatment options. Interestingly, therapeutic hypo-
thermia adversely affected the proliferation rates of HBMECs 
and HAs under normoglyacemic conditions (Figs. 2 and 3).
Therapeutic hypothermia potentiates 
the suppressive effects of PKC‑β or Nox2 inhibition 
on oxidative stress
Hyperglycaemia increased the level of superoxide anion in 
both HBMEC and HA through an increase in Nox activity. 
Therapeutic hypothermia as well as inhibition of PKC-β and 
Nox-2 by LY333531 and gp91ds-tat, respectively negated 
these increases in both cell lines. Combination of therapeu-
tic hypothermia with either inhibitor decreased superoxide 
anion production and Nox activity below the levels seen in 
Fig. 3  The effects of single 
or combinatory treatments 
with therapeutic hypothermia, 
LY333531 and gp91ds-tat on 
human astrocytes (HAs) wound 
closure. While hyperglycae-
mia dramatically impaired the 
speed of HA wound repair. 
The combination of therapeutic 
hypothermia with LY333531 
or gp91ds-tat accelerated the 
rate of wound healing com-
pared to any single therapeutic 
option. Co-exposure of HAs 
to therapeutic hypothermia 
and normoglycameia reduced 
the level HA wound repair to 
the levels observed in hyper-
glycaemic settings (A). Graph 
showing the wound closure 
speed across all experimental 
groups (B). Data are expressed 
as mean ± s.e.m. from three 
different experiments. *P < 0.05 
versus normoglycaemia (NG), 
#P < 0.05 versus HG, ΨP < 0.05 
versus HG + TH, γP < 0.05 
versus HG + LY333531, and 
ςP < 0.05 versus gp91ds-tat. 
NG, normoglycaemia; HG, 
hyperglycaemia; TH, therapeu-
tic hypothermia
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control cells, maintained in normoglycaemic and normother-
mic conditions. In contrast, exposure of normoglycaemic 
cells to therapeutic hypothermia did not alter the basal levels 
of superoxide anion production and Nox activity in either 
cell line (Fig. 4).
Therapeutic hypothermia augments the protective 
effects of PKC‑β or Nox2 inhibition on cytoskeleton
Physical, chemical or humoral changes in the cellular 
microenvironment dramatically affect actin cytoskeleton 
which induce a shift from G-actin to F-actin and promote 
the formation of contractile actin bundles called stress 
fibres. Assessment of actin cytoskeleton in HBMECs and 
HAs through rhodamine-phalloidin staining revealed that 
hyperglycaemia dramatically induced the formation of stress 
fibres in a time-dependent manner. Exposure to therapeutic 
hypothermia also promotes stress fibres in both cell lines, 
maintained in normoglycaemic settings, in a time-depend-
ent manner (Figs.  5–6). While the LY333531, gp91ds-
tat and therapeutic hypothermia reduced the amount of 
hyperglycaemia-induced stress fibres, combination of hypo-
thermia with either inhibitor effectively neutralised the effect 
of hyperglycaemia on actin cytoskeleton. The quantification 
of stress fibres intensities further corroborated that combi-
national therapies were more effective in repairing actin 
cytoskeleton organisation of HBMECs and HAs compared 
to any single treatments, as indicated by the lesser magni-
tude of stress fibres intensities observed in combinational 
approaches (Fig. 7).
Discussion
The BBB, composed of endothelial cells, astrocytic end‐feet, 
pericytes and basement membrane, serves as an important 
dynamic semipermeable barrier to maintain cerebral homeo-
stasis. The disruption of BBB, characterised by increased 
interendothelial cell permeability, is considered as a key 
pathology in the development of cerebral injury and subse-
quent neurological impairment during or after an ischaemic 
stroke (Jiang et al. 2018). The presence of comorbidities, 
Fig. 4  The effects of single or combinatory treatments with thera-
peutic hypothermia, LY333531 and gp91ds-tat on Nox2 activity and 
superoxide anion release in human brain microvascular endothe-
lial cells (HBMEC) and astrocytes (HAs). Exposure of either cell 
line to hyperglycaemia led to significant increases in oxidase activ-
ity and superoxide anion generation. While treatment with single 
therapies effectively inhibited both parameters, co-application of 
therapeutic hypothermia with LY333531 or gp91ds-tat appeared to 
be more effective in reducing Nox2 activity A and B and superoxide 
anion release C and D in both HBMEC and HA subjected to hyper-
glycaemic insult for 120 h. Data are expressed as mean ± SEM from 
three different experiments. *P < 0.05 versus normoglycaemia (NG), 
#P < 0.05 versus HG, ΨP < 0.05 versus HG + TH, γP < 0.05 versus 
HG + LY333531, and ςP < 0.05 versus gp91ds-tat. NG, normoglycae-
mia; HG, hyperglycaemia; TH, therapeutic hypothermia
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in particular hyperglycaemia, is known to further exacer-
bate disruption of the BBB after an ischaemic stroke, in that 
thickening of the capillary basement membrane, induction 
of oxidative stress and neuronal and endothelial cell apop-
tosis appear to play an important role (Venkat et al. 2017). 
Inevitably, ischaemic stroke patients with DM manifest more 
severe neurological deficits and have higher fatality rates 
(Li et al. 2013). Besides, diabetic stroke patients treated 
with rtPA manifest higher rates of intracranial haemorrhage 
(Masrur et al. 2015; Thorén et al. 2017; Yu et al. 2016). 
Hence, it is of great therapeutic significance to explore 
mechanisms that may be utilised to improve outcomes in 
diabetic stroke patients.
Despite a large number of agents have, over the years, 
been shown to protect cerebrovascular integrity and func-
tion in experimental settings, the subsequent clinical trials 
performed with the same agents failed to replicate these 
favourable effects. One of the main drawbacks regarding 
translational stroke research is that the majority of the agents 
used in the above-mentioned clinical trials have focused on 
a single pathway pertaining to either recanalisation of ves-
sels or excitotoxicity to reduce neuronal death, while many 
other processes are involved spatially and temporally in the 
pathophysiology of stroke (Alwjwaj et al. 2021; Loach and 
Bayraktutan 2016). In this context, therapeutic hypothermia 
capable of targeting multiple pathways, notably oxidative 
stress, inflammatory responses, metabolic disruption and 
cell death signals may be a potentially effective procedure 
(Loach and Bayraktutan 2017). Indeed, therapeutic hypo-
thermia has long been considered as an efficacious thera-
peutic option for patients with cardiac arrest or for new-
borns with hypoxic-ischaemic encephalopathy (Bernard 
et al. 2002; Shankaran et al. 2005). Furthermore, therapeu-
tic hypothermia has been shown to reduce infarct size and 
neurological deficits by at least 30% in animal models of 
ischaemic stroke and protect the integrity of the cerebral 
barrier and its function during ischaemia/reperfusion injury 
(Mathur and Bayraktutan 2016, 2017; van der Worp et al. 
2007). However, whether therapeutic hypothermia may pro-
vide cerebrovascular protection in diabetic stroke patients 
Fig. 5  Representative images of actin cytoskeleton in human brain 
microvascular endothelial cells (HBMEC) cultured under normo-
glycaemic and hyperglycaemic (6–120  h) conditions in the absence 
or presence of therapeutic hypothermia. Treatment of normoglycae-
mic cells with therapeutic hypothermia or exposure to hyperglycae-
mic insult led to prominent actin stress fibre formation (indicated by 
white arrows) in HBMEC in a time-dependent manner. Therapeutic 
hypothermia significantly attenuated the impact of hyperglycaemia on 
stress fibre formation. Scale bars = 20 μm. NG, normoglycaemia; NT, 
normothermia; HG, hyperglycaemia; TH, therapeutic hypothermia
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or in the experimental settings of hyperglycaemic cerebral 
barrier injury remain unclear.
Using an interactive in vitro model of the human cerebral 
barrier established by concurrent culture of brain microvas-
cular endothelial cells, astrocytes and pericytes, the current 
study has shown that therapeutic hypothermia can in fact 
protect BBB from the disruptive effects of hyperglycaemia. 
In light of the well-established roles of PKC-β and Nox2 
in hyperglycaemic BBB damage, studies combining thera-
peutic hypothermia with the inhibitors of these pathways 
led to greater protection from hyperglycaemic damage, as 
shown by the significant increases in TEER and concomitant 
decreases in NaF flux across the barrier compared to single 
therapy groups. TEER measurement constitutes the most 
extensively used methodology to assess BBB integrity. It 
is based on measurement of the electrical resistance across 
the monolayers that form the experimental cerebral barrier 
and indicates the extent of tight junctional unity between 
neighbouring endothelial cells. Hence, it is considered as 
a strong and reliable indicator of the tightness of the mon-
olayer (Srinivasan and Kolli 2019; Stone et al. 2019). The 
measurement of the amount of solute crossing the cellular 
barrier, on the other hand, provides invaluable information 
on the extent of openings between tight junctions and there-
fore serves as an important marker for the functional status 
of the BBB (Helms et al. 2016; Zucco et al. 2005; Sun et al. 
2021). The changes observed in TEER readings and NaF 
flux in the present study strongly implies a hyperglycaemia-
mediated breakdown of the BBB integrity and function, 
respectively (Helms et al. 2016). Suppression of PKC-β 
and Nox2 has previously been correlated with decreased 
apoptosis of endothelial cells exposed to pathological stim-
uli including hyperglycaemia and inflammatory cytokines 
like TNF-α (Abdullah and Bayraktutan 2016; Shao and 
Bayraktutan 2014). It is likely that therapeutic hypother-
mia may further decrease the endothelial cell apoptosis to 
improve barrier integrity. Profound decreases observed in 
oxidative stress, as evidenced by concomitant decreases in 
pro-oxidant Nox activity and superoxide anion production 
along with faster and more effective repair of HBMEC and 
astrocyte damage, attested by wound scratch assay, may also 
Fig. 6  Representative images of actin cytoskeleton staining in human 
brain microvascular endothelial cells (HBMEC) cultured under 
hyperglycaemic conditions (6–120  h) in the presence of LY333531 
and gp91ds-tat alone or together with therapeutic hypothermia. Albeit 
treatment with PKC-β or Nox2 inhibitor decreased the extent of stress 
fibres formation (indicated by white arrows) in HBMECs, the combi-
natory therapeutic approaches appeared to be more effective in negat-
ing the impact of hyperglycaemia. Scale bars = 20  μm. NG, normo-
glycaemia; NT, normothermia; HG, hyperglycaemia; TH, therapeutic 
hypothermia
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contribute to better responses obtained with the combination 
therapy.
Polymerisation of actin filaments form linear stress 
fibres and create tensile centripetal force leading to open-
ing of intercellular gaps between endothelial cells (Chen 
et al. 2013; Srivastava and Bayraktutan 2017). Experiments 
focusing on the impact of different therapeutic approaches 
on actin cytoskeleton have shown better preventive effects 
with combinatory approach in both HBMECs and HAs. In 
support of our findings, exposure to therapeutic hypother-
mia has also been shown to reduce neurological deficits, 
cerebral infarction, brain oedema volume and BBB hyper-
permeability in an experimental model of diabetic stroke in 
that inhibition of cell death appeared to play a key role (Tu 
et al. 2019). Intriguingly, despite being highly beneficial in 
hyperglycaemic settings, therapeutic hypothermia displayed 
adverse effects on BBB function as well as HBMEC and 
astrocyte wound closure and actin cytoskeleton organisa-
tion under normoglycaemic conditions without affecting 
the level of oxidative stress. Consistent with these findings, 
significant decreases in proliferation and increases in apop-
tosis have been observed in human umbilical vein endothe-
lial cells exposed to therapeutic hypothermia where altera-
tions in the levels of various inflammatory factors, such as 
IL-6, IL-8, COX-2 and MCP-1 appear to play a role (Dies-
tel et al. 2008). The increases in inflammatory mediators, 
particularly IL-6, and apoptosis of astrocyte, neuronal and 
microglial cells after exposing these cells to therapeutic 
hypothermia in normoglycaemic environment also reported 
by other studies (Schmitt et al. 2006, 2007), further support-
ing our findings that therapeutic hypothermia may impair 
cellular and molecular function of cerebral cells in physi-
ological settings. We also have previously shown that inac-
tivation of PKC-β signalling pathway under normal condi-
tions does not affect actin cytoskeleton formation, RhoA/
Rho-kinase/MLC2 pathway activity and ZO-1 expression 
but increases the expression of a main tight junction protein, 
occludin in HBMECs (Srivastava et al. 2013). Moreover, the 
inhibition of NADPH oxidase activity in physiological set-
tings adversely affect endothelial cell growth, an important 
Fig. 7  Representative images of actin cytoskeleton staining in human 
astrocytes (HAs) cultured under normoglycaemic and hyperglycae-
mic (6–120  h) conditions in the absence or presence of therapeutic 
hypothermia. Treatment of normoglycaemic HAs with therapeutic 
hypothermia or exposure to hyperglycaemia markedly elevated actin 
stress fibre formation (indicated by white arrows) in a time-dependent 
manner. Therapeutic hypothermia significantly attenuated the impact 
of hyperglycaemia on stress fibre formation. Scale bars = 20 μm. NG: 
normoglycaemia. NG, normoglycaemia; NT, normothermia; HG, 
hyperglycaemia; TH, therapeutic hypothermia
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mechanism in establishment and repair of endothelial barrier 
(Bayraktutan 2004, 2005).
Exposure to hyperglycaemia induces a series of patho-
logical mechanisms through successive activations of dia-
cylglycerol (DAG) and PKC signalling pathway which in 
turn activate pro-oxidant enzyme Nox, trigger inflamma-
tory responses and impair cellular architecture (Teodoro 
et al. 2019). Consistent with the previous studies (Huang 
et al. 2019; Lorenzi et al. 1985; Zhu et al. 2015), exposure 
of HBMEC or astrocytes to hyperglycaemia in the current 
study has also negatively influenced the speed of wound 
repair of these cells which in part may be explained by 
excessive release of ROS, notably superoxide anion in these 
settings. Although superoxide anion plays a crucial role in 
physiological function, particularly in intracellular commu-
nication, neurotransmitter release, and immune defence sys-
tem, its exaggerated availability in hyperglycaemic settings 
is coupled to markedly reduce proliferation rate of endothe-
lial cells. In addition to this, the excessive amount of super-
oxide anion also disrupts normal cellular structure and TJ 
formation and thus compromises BBB integrity and function 
(Abdullah et al. 2015; Shao and Bayraktutan 2014; Zanetti 
et al. 2001). Since Nox is the primary source of superoxide 
anion and DAG-PKC-Nox pathway is thought to be respon-
sible for much of the above mentioned detrimental effects, 
it is no surprise that this pathway is known as “dangerous 
metabolic route in diabetes” and has therefore received a 
great deal of attention to ameliorate diabetic microvascular 
and macrovascular complications. Although the inhibition of 
DAG as the upstream component of this metabolic pathway 
appears to be the logical option to interrupt this signalling 
cascade, this has so far not been materialised due to its bio-
chemical complexity (Volpe et al. 2018). Hence, PKC and 
Nox have emerged as potential therapeutic targets in diabetic 
stroke and associated complications.
The PKC family of enzymes are classified into three sub-
groups based on sequence homology and activation mecha-
nisms, of which PKC-β contributes the most to total PKC 
activity and plays a seminal role in exacerbating in vitro 
cerebral barrier damage under hyperglycaemic condition 
Fig. 8  Representative images of actin cytoskeleton staining in human 
astrocytes (HAs) cultured under hyperglycaemic conditions (6–120 h) 
in the presence of LY333531 and gp91ds-tat alone or together with 
therapeutic hypothermia. Although treatment with PKC-β or Nox2 
inhibitor alone reduced the extent of stress formation in hyperglycae-
mic HAs (indicated by white arrows), the magnitude of stress fibre 
suppression was greater when combined with therapeutic hypother-
mia. Scale bars = 20  μm. NG, normoglycaemia; NT, normothermia; 
HG, hyperglycaemia; TH, therapeutic hypothermia
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(Shao and Bayraktutan 2013; Srivastava et al. 2013). PKC-β 
isoform-selective inhibitors have been shown to be safe for 
human use and exert some degree of therapeutic benefit in 
patients with diabetic retinopathy (Aiello et al. 2006). They 
have also been shown to prevent brain oedema by reversing 
BBB damage in translational settings of diabetic ischaemic 
stroke (Cipolla et al. 2011). The cerebral barrier-protection 
realised by PKC-β inhibition may in part be due to the fact 
Fig. 9  The quantification of the 
length of stress fibre formation 
in human brain microvascular 
endothelial cells (HBMEC) 
and human astrocytes (HAs) 
cultured under normoglycaemic 
and hyperglycaemic (6–120 h) 
conditions in the presence 
of therapeutic hypothermia, 
LY333531, gp91ds-tat or com-
bination of these agents. The 
length of stress fibres formation 
in each cell was accumulated 
and then normalised to cells 
maintained under normal condi-
tions (NG) to reflect potential 
changes. Both exposure to 
hyperglycaemic injury and 
treatment of normoglycaemic 
cells with therapeutic hypother-
mia induced actin stress fibres 
formation in both cell lines in a 
time dependent manner. While 
single therapies with therapeutic 
hypothermia, PKC-β or Nox2 
inhibitor reduced the level 
of stress fibre formation, the 
combinatory approaches were 
more effective in suppressing 
actin cytoskeleton organisa-
tion compared to any single 
treatment, as evidenced by the 
emergence of shorter stress 
fibres in both cells. *P < 0.05 
versus normoglycaemia (NG), 
#P < 0.05 versus HG, ΨP < 0.05 
versus HG + TH, γP < 0.05 
versus HG + LY333531, and 
ςP < 0.05 versus gp91ds-tat. 
NG, normoglycaemia; HG, 
hyperglycaemia; TH, therapeu-
tic hypothermia
Metabolic Brain Disease 
1 3
that this isoenzyme acts upstream to a wide range of com-
ponents, notably Nox, known to affect BBB homeostasis. 
Substantial increases in Nox subunit expression and ensu-
ing overall enzymatic activity have been documented in 
experimental models of diabetic stroke and correlated with 
greater cerebral infarct size and severe neurological deficits 
(Kusaka et al. 2004). Significant increases in Nox activity, 
particularly Nox2 isoform, and superoxide generation have 
also been documented in cerebral endothelial cells cultured 
under hyperglycaemic conditions (Allen and Bayraktutan 
2009; Ulker et al. 2004).
Genetic deletion or pharmacological inhibition of PKC-β 
in HBMECs exposed to hyperglycaemic insult has also been 
linked to reduced DNA fragmentation rates, caspase 3/7 
activity and pro-apoptotic Bax protein release, ascribing a 
crucial role to PKC-β in endothelial cell apoptosis (Shao and 
Fig. 10  The effect of hyper-
glycaemia on blood–brain 
barrier (BBB) integrity in 
the absence or presence of 
therapeutic hypothermia alone 
or together with inhibitors 
targeting PKC-β or Nox2. 
Through successive activation 
of diacylglycerol and PKC-β, 
hyperglycaemia increases the 
activity of NADPH oxidase 
which ultimately leads to BBB 
breakdown through generating 
excessive levels of superoxide 
anion, activating transcription 
factor NF-κB and regulating the 
synthesis, release and recruit-
ment of various inflammatory 
mediators. Induction of stress 
fibre formation, tight junction 
reorganisation, apoptosis as well 
as inhibition of the prolifera-
tive and migratory capacity of 
endothelial cells and astrocytes 
also appear to contribute to the 
overall BBB damage. While 
treatments with therapeutic 
hypothermia alone effectively 
suppress the deleterious effects 
of hyperglycaemia on BBB, its 
combination with approaches 
negating the activity of PKC-β 
or Nox2 provide greater BBB-
restorative capacity
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Bayraktutan 2014). In addition, the inhibition of PKC-β has 
been shown to attenuate increases in endothelial cell uroki-
nase plasminogen activator (uPA) activity evoked by TNF-
α, a prominent pro-inflammatory cytokine during the acute 
phase of an ischaemic injury, implying that PKC-β may also 
regulate the plasminogen-plasmin system (Abdullah and 
Bayraktutan 2016). As an upstream regulator of NF-κB, a 
transcription factor that regulates multiple aspects of innate 
and adaptive immune reactions, the increased availability 
of PKC-β in diabetic animals has been shown to account for 
vascular inflammatory response and accelerated atheroscle-
rosis (Kong et al. 2013; Lutzny et al. 2013). Indeed, acqui-
sition of better integrity and function of BBB in an animal 
model of acute inflammation treated with a PKC-β inhibitor 
further emphasise the seminal role of PKC-β in induction 
of inflammatory responses and ensuing BBB dysfunction 
(Lanz et al. 2013). It is of note here that PKC-β-mediated 
phosphorylation and subsequent degradation of occludin and 
ZO-1, major tight junction proteins, may also be involved in 
BBB dysfunction (Avila-Flores et al. 2001; Chen et al. 2002; 
Murakami et al. 2012).
Considering the diversity of pathways targeted by PKC-β 
and the consistent association of Nox with these pathways, 
the present study specifically investigated the preventive/
restorative impact of Nox2 inhibition alone or with thera-
peutic hypothermia on BBB in hyperglycaemic settings. 
Data generated show better barrier-protective impact when 
therapeutic hypothermia is applied along with Nox2 inhibi-
tor. The mechanism of reparative effects of these combi-
national therapies is illustrated in Fig. 9. The discovery of 
remarkably smaller cerebral infarcts size in Nox2-deficient 
mice subjected to MCAO and considerably lower oxidative 
stress level after knockdown of Nox-2 activity in neuronal 
cells exposed to hyperglycaemia with ischaemic damage 
corroborate the therapeutic benefits of Nox2 inhibition dur-
ing hyperglycaemic injury (Kahles et al. 2007; Zeng et al. 
2018) Figs. 8–10.
Accumulating evidence has displayed that the combi-
nation of therapeutic hypothermia with other therapeutic 
agents achieves better effectiveness in repairing neurovas-
cular damage following ischaemic stroke. For instance, the 
combination of therapeutic hypothermia with calcium and 
glutamate antagonist (magnesium) and with an antioxi-
dant (tirilazad) enhances the restorative role of therapeu-
tic hypothermia on cerebrovascular damage after ischae-
mia, as ascertained by marked reductions infarct volume 
and neurological deficits in MCAO rats (Zausinger et al. 
2003). Similarly, the combination of mild hypothermia 
with dizocilpine (glutamate antagonist), human urinary 
kallidinogenase (kinin activator) or neuroglobin (neuron 
oxygen-binding protein) is more efficacious in protecting 
ischaemia/reperfusion-induced neuronal injury compared 
to single treatment regimens (Gao et al. 2014; Wei et al. 
2018). Better protection of the cerebral barrier integrity 
and function through combination of a PKC-β or a Nox2 
inhibitor with therapeutic hypothermia in the present study 
further corroborate the higher efficacy of combinational 
strategy in hyperglycaemic conditions.
In conclusion, the current study has shown that thera-
peutic hypothermia augments the BBB-restorative effects 
of PKC-β or Nox2 inhibition in hyperglycaemic settings 
by reducing oxidative stress, restoring actin cytoskeleton 
formation and increasing the proliferation and directed 
migration of HBMECs and HAs, two main cellular com-
ponents of the BBB.
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